A phase 2 clinical trial (NCT02395627) [10] evaluated patients with ER+ breast cancer upon treatment with histone deacetylase (HDAC) inhibitor (vorinostat), ER antagonist (tamoxifen) and PD1-blocking Ab (pembrolizumab). Here, PDCD1 is linked to breast carcinoma.